BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10

• Press Releases

  NYU Langone Health Announces Renowned Psychiatrist to Lead Interventional Psychiatry Services

  October 7, 2025

   · 

  4 min read
• Press Releases

  RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE® to Treat Complex Spine Fractures

  October 7, 2025

   · 

  3 min read
• Press Releases

  RoosterBio and Secretome Therapeutics Announce Successful Completion of Large Scale Bioreactor Production for Clinical Stage Cell Therapy Candidate STM-01

  October 7, 2025

   · 

  4 min read
• Press Releases

  Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates

  October 7, 2025

   · 

  6 min read
• Press Releases

  Orca Bio Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T® to Treat Hematological Malignancies

  October 7, 2025

   · 

  3 min read
• Press Releases

  Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event

  October 7, 2025

   · 

  13 min read
• Press Releases

  Pridopidine Pivotal Phase 3 ALS Study Unveiled at NEALS 2025 Annual Meeting

  October 7, 2025

   · 

  8 min read
• Press Releases

  Alpha Cognition to Present Clinical Data at ASCP Annual Meeting

  October 7, 2025

   · 

  7 min read
• Press Releases

  BrYet US, Inc. Receives Approval to Initiate in Australia a First-in-Human Phase 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement

  October 7, 2025

   · 

  5 min read
• Press Releases

  Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)

  October 7, 2025

   · 

  7 min read